Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2008
Novel strategies for granulocyte colony-stimulating factor treatment of severe prolonged neutropenia suggested by mathematical modeling
Eliezer Shochat, Vered Rom-Kedar
Plos One
|
May 14, 2010
Bistability and bacterial infections
Roy Malka, Eliezer Shochat, Vered Rom-Kedar
Bulletin of Mathematical Biology
|
October 24, 2002
Human haematopoiesis in steady state and following intense perturbations
Eliezer Shochat, Salomon M Stemmer, Lee Segel
Bulletin of Mathematical Biology
|
April 26, 2007
Mathematical model of BCG immunotherapy in superficial bladder cancer
Svetlana Bunimovich-Mendrazitsky, Eliezer Shochat, Lewi Stone
The Journal of Clinical Investigation
|
July 24, 2012
Evidence for bistable bacteria-neutrophil interaction and its clinical implications
Roy Malka, Baruch Wolach, Ronit Gavrieli, et al.
Cancer Informatics
|
December 19, 2014
Semantically linking in silico cancer models
David Johnson, Anthony J Connor, Steve McKeever, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 13, 2012
Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials
Françoise Kraeber-Bodéré, Thomas Carlier, Valérie Meresse Naegelen, et al.
Journal of the Royal Society, Interface
|
August 21, 2015
An integrated approach to quantitative modelling in angiogenesis research
Anthony J Connor, Radosław P Nowak, Erica Lorenzon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 5, 2012
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors
Maria Martinez-Garcia, Udai Banerji, Joan Albanell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 7, 2012
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors
Suzanne Leijen, Mark R Middleton, Patricia Tresca, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2008
Novel strategies for granulocyte colony-stimulating factor treatment of severe prolonged neutropenia suggested by mathematical modeling
Eliezer Shochat, Vered Rom-Kedar
Plos One
|
May 14, 2010
Bistability and bacterial infections
Roy Malka, Eliezer Shochat, Vered Rom-Kedar
Bulletin of Mathematical Biology
|
October 24, 2002
Human haematopoiesis in steady state and following intense perturbations
Eliezer Shochat, Salomon M Stemmer, Lee Segel
Bulletin of Mathematical Biology
|
April 26, 2007
Mathematical model of BCG immunotherapy in superficial bladder cancer
Svetlana Bunimovich-Mendrazitsky, Eliezer Shochat, Lewi Stone
The Journal of Clinical Investigation
|
July 24, 2012
Evidence for bistable bacteria-neutrophil interaction and its clinical implications
Roy Malka, Baruch Wolach, Ronit Gavrieli, et al.
Cancer Informatics
|
December 19, 2014
Semantically linking in silico cancer models
David Johnson, Anthony J Connor, Steve McKeever, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 13, 2012
Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials
Françoise Kraeber-Bodéré, Thomas Carlier, Valérie Meresse Naegelen, et al.
Journal of the Royal Society, Interface
|
August 21, 2015
An integrated approach to quantitative modelling in angiogenesis research
Anthony J Connor, Radosław P Nowak, Erica Lorenzon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 5, 2012
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors
Maria Martinez-Garcia, Udai Banerji, Joan Albanell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 7, 2012
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors
Suzanne Leijen, Mark R Middleton, Patricia Tresca, et al.
Page
of 2